The pigment that makes berries purple may tune blood sugar and cholesterol

Anthocyanins are the plant compounds responsible for the deep red, purple and blue colours of berries and other foods, and they have been tested in numerous clinical trials for effects on blood sugar and blood lipids. Individual trials pointed in different directions, and their results had never been quantitatively synthesised and systematically evaluated. Blood glucose control and cholesterol are two of the central levers in cardiometabolic disease, so a food-derived compound that shifts both would be of genuine interest. This review set out to pool the randomised evidence across healthy populations and those with existing cardiometabolic conditions.

The authors searched five databases and a trials registry up to February 2017 for randomised controlled trials lasting at least 2 weeks that assessed anthocyanins' effects on glycaemic control, insulin sensitivity or lipids, whether as primary or secondary outcomes. Thirty-two trials with 1491 participants were eligible for the meta-analysis. Study quality was assessed with the Cochrane Risk of Bias tool, and effects were pooled as standardised mean differences using random-effects models. Meta-regression, sensitivity and subgroup analyses probed whether trial characteristics influenced the overall results.

Anthocyanins significantly reduced fasting glucose, glucose measured 2 hours after a meal, and glycated haemoglobin, the longer-term marker of blood sugar control. They also lowered total cholesterol and LDL cholesterol. The improvements held up in sensitivity analyses that excluded trials with a high or unclear risk of bias, which strengthens confidence in the direction of the effects. Statistical disagreement between trials was high across outcomes, however, so the sizes of the pooled effects are less certain than their direction. The authors note that optimal formulation and dosage remain unresolved.

This synthesis supports the idea that anthocyanins have measurable effects on cardiometabolic risk markers rather than simply travelling alongside otherwise healthy diets. It goes further than observational berry research by pooling randomised trials, where the intervention is assigned rather than chosen. The heavy disagreement between trials, and the mixture of populations, formulations and doses, means the field still lacks a clear recipe. The authors call for well-designed longer trials to establish lasting effects and pin down the best form and amount, so this is a foundation rather than a finished story.

This is a reason to take deeply coloured plant foods seriously as more than garnish: the compounds that give them their colour improved blood sugar markers and cholesterol in pooled trial data. Because the trials tested anthocyanin interventions directly, the effect is more than a healthy-eater correlation. That said, the studies varied widely, and the ideal dose and form are unknown, so the finding informs food choices more than it validates any particular product. The outcomes here are risk markers, not disease itself, which longer trials would be needed to address.